Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Fusion proteins useful for DC-based immunotherapy of tumors

Dec. 5, 2001

Ivax immunotoxin for brain cancer reportedly effective at very low intratumoral doses

Dec. 3, 2001

Biomira suspends two cancer vaccine programs to focus on advanced products

Dec. 3, 2001

Boehringer Ingelheim and ImmunoGen to develop new TAP product

Nov. 30, 2001

Orphan drug status granted for IL-13-PE38 for the treatment of malignant glioma

Nov. 28, 2001

Phase II trial of GVAX cancer vaccine for acute myelogenous leukemia set to commence

Nov. 28, 2001

Cell Genesys and Japan Tobacco modify cancer vaccines agreement

Nov. 27, 2001

Early phase I data for CEA/TRICOM encouraging

Nov. 23, 2001

Virulizin enters phase III for treatment of pancreatic cancer

Nov. 22, 2001

PI-88 may have use in the treatment of leukemia

Nov. 21, 2001

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...